Susquehanna International Group, LLP 9 Meters Biopharma, Inc. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	SELL	$0.21 - $0.32 $10,206 - $15,552	-48,600 Reduced 7.61%	589,800 $130,000
Q2 2022 Aug 15, 2022	BUY	$0.26 - $0.64 $61,490 - $151,360	236,500 Added 58.85%	638,400 $166,000
Q1 2022 May 16, 2022	BUY	$0.52 - $1.0 $47,528 - $91,400	91,400 Added 29.44%	401,900 $241,000
Q4 2021 Feb 14, 2022	SELL	$0.85 - $1.33 $737,375 - $1.15 Million	-867,500 Reduced 73.64%	310,500 $304,000
Q3 2021 Nov 15, 2021	SELL	$1.03 - $1.41 $5,253 - $7,191	-5,100 Reduced 0.43%	1,178,000 $1.53 Million

Q2 2021 Aug 11, 2021	SELL	$1.04 - $1.5 $581,360 - $838,500	-559,000 Reduced 32.09%	1,183,100 $1.3 Million
Q1 2021 May 17, 2021	BUY	$0.84 - $2.16 $1.32 Million - $3.4 Million	1,574,400 Added 938.82%	1,742,100 $2.04 Million
Q4 2020 Feb 16, 2021	BUY	$0.65 - $1.11 $3,705 - $6,327	5,700 Added 3.52%	167,700 $144,000
Q3 2020 Nov 16, 2020	BUY	$0.48 - $0.84 $57,456 - $100,548	119,700 Added 282.98%	162,000 $132,000
Q2 2020 Aug 14, 2020	BUY	$0.43 - $0.74 $18,189 - $31,302	42,300 New	42,300 $24,000

67.9K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.